

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 December 2004 (16.12.2004)

PCT

(10) International Publication Number
WO 2004/108955 A1

(51) International Patent Classification⁷: **C12Q 1/68**,
C12N 15/00, A01K 67/00

[AU/AU]; 56 Churchill Street, Mont Albert, VIC 3127 (AU).

(21) International Application Number:
PCT/AU2004/000749

(74) Agents: **HUGHES, E., John, L.** et al.; 1 Nicholson Street, Melbourne, VIC 3000 (AU).

(22) International Filing Date: 4 June 2004 (04.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2003902788 4 June 2003 (04.06.2003) AU

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): **THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH** [AU/AU]; Royal Parade, Parkville, VIC 3052 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CROKER, Ben** [AU/AU]; 51 Kurrawan Street, Tamworth, NSW 2340 (AU). **ROBERTS, Andrew** [AU/AU]; 160 Highfield Road, Camberwell, VIC 3124 (AU). **METCALF, Don** [AU/AU]; 268 Union Road, Balwyn, VIC 3103 (AU). **ALEXANDER, Warren** [AU/AU]; 13 Park Street, Moonee Ponds, VIC 3039 (AU). **HILTON, Doug** [AU/AU]; 244 Research Road, Warrandyte, VIC 3113 (AU). **NICOLA, Nicos**

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF IDENTIFYING COMPOUNDS WHICH MODULATE GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) DEPENDENT PROCESSES BY MODULATION OF THE LEVELS OF A SUPPRESSOR OF CYTOKINE SIGNALING (SOCS)

(57) Abstract: The present invention relates generally to compounds which modulate cytokine-dependent processes. More particularly, the compounds of the present invention modulate responses to a colony stimulating factor and even more particularly to granulocyte-colony stimulating factor (G-CSF) by modulating the levels of molecules which inhibit G-CSF such as but not limited to a suppressor of cytokine signaling (SOCS) and in particular SOCS-3. The present invention further contemplates methods for regulating G-CSF-dependent processes by contacting cells in vitro with or administering to a subject a compound which up- or down-regulates the level of activity of G-CSF by modulating the level or activity of a SOCS molecule such as SOCS-3. The instant compounds are further useful for modulating a range of G-CSF-induced cellular responses including neutrophil recovery after chemotherapy or radiotherapy, mobilizing stem and progenitor cells, treating infection and treating inflammatory conditions.



WO 2004/108955 A1

**METHODS OF IDENTIFYING COMPOUNDS WHICH MODULATE
GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) DEPENDENT
PROCESSES BY MODULATION OF THE LEVELS OF A SUPPRESSOR OF
CYTOKINE SIGNALING (SOCS)**

BACKGROUND OF THE INVENTION

5 FIELD OF THE INVENTION

The present invention relates generally to compounds which modulate cytokine-dependent processes. More particularly, the compounds of the present invention modulate responses to a colony stimulating factor and even more particularly to granulocyte-colony stimulating factor (G-CSF) by modulating the levels of molecules which inhibit G-CSF such as but not
10 limited to a suppressor of cytokine signaling (SOCS) and in particular SOCS-3. The present invention further contemplates methods for regulating G-CSF-dependent processes by contacting cells *in vitro* with or administering to a subject a compound which up- or down-regulates the level of activity of G-CSF by modulating the level or activity of a
15 SOCS molecule such as SOCS-3. The instant compounds are further useful for modulating a range of G-CSF-induced cellular responses including neutrophil recovery after chemotherapy or radiotherapy, mobilizing stem and progenitor cells, treating infection and treating inflammatory conditions.

20 DESCRIPTION OF THE PRIOR ART

Bibliographic details of the publications referred to in this specification are also collected at the end of the description.

25 Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.

The suppressor of cytokine signaling (SOCS) proteins are a family of eight SH2 domain
30 containing proteins which includes the cytokine-inducible SH2 (CIS) domain-containing

- 2 -

protein and SOCS-1 to 7. Studies in many laboratories have implicated SOCS proteins in the attenuation of cytokine action through inhibition of the Janus Kinase (JAK)/Signal Transducer and Activators of Transcription (STAT) signal transduction pathway. SOCS proteins operate as part of a classical negative feedback loop, in which activation of
5 cytokine signaling leads to their expression. Once produced, SOCS proteins bind to key components of the signaling apparatus to deactivate and possibly target them for degradation *via* a conserved C-terminal motif, called the "SOCS Box", that recruits ubiquitin ligases (reviewed in Krebs and Hilton, *J. Cell Sci.* 113(16): 2813-2819, 2000; Yasukawa *et al.*, *Annu. Rev. Immunol.* 18: 143-164, 2000; Greenhalgh and Hilton, *J.*
10 *Leukoc. Biol.* 70(3): 348-356, 2001).

While *in vitro* studies have suggested that SOCS proteins may be promiscuous in their activity, gene deletion studies in mice have highlighted their importance in a limited number of signaling pathways. SOCS-1 is a key regulator of IFN- γ signaling, T-cell
15 homeostasis and lactation (Marine *et al.*, *Cell* 98(5): 609-616, 1999; Alexander *et al.*, *Cell* 98(5): 597-608, 1999; Lindeman *et al.*, *Genes Dev.* 15(13): 1631-1636, 2001), while SOCS-3 is thought to play crucial roles in erythropoiesis and placental function (Marine *et al.*, *Cell* 98(5): 617-627, 1999; Roberts *et al.*, *Proc. Natl. Acad. Sci. USA* 98(16): 9324-9329, 2001). CIS-deficient mice are reported to have no phenotype, although CIS
20 transgenic mice display growth retardation and defects in mammary development which are accompanied by reductions in STAT5 phosphorylation (Matsumoto *et al.*, *Mol. Cell Biol.* 19(9): 6396-6407, 1999) and show similarities to the phenotypes observed in STAT5a and STAT5b deficient mice (Teglund *et al.*, *Cell* 93(5): 841-850, 1998; Udy *et al.*, *Proc. Natl. Acad. Sci. USA* 94(14): 7239-7244, 1997; Liu *et al.*, *Genes Dev.* 11(2):
25 179-186, 1997).

SOCS-2 deficient animals exhibit accelerated post-natal growth resulting in a 30-50% increase in body weight by 12 weeks of age, significant increases in bone and body lengths, thickening of the skin due to collagen deposition and increases in internal organ size
30 (Metcalf *et al.*, *Nature* 405(6790): 1069-1073, 2000). This phenotype has striking

- 3 -

similarities to those of insulin-like growth factor (IGF)-I and growth hormone (GH) transgenic mice (Palmiter *et al.*, *Science* 222(4625): 809-814, 1983; Mathews *et al.*, *Endocrinology* 123(6): 2827-2833, 1988). Further investigation of the SOCS-2^{-/-} phenotype identified significant increases of IGF-I mRNA in some tissues and lower levels of major urinary protein (MUP) the expression of which is regulated by intermittent GH secretion (Metcalf *et al.*, 2000, *supra*). Recently, STAT5 phosphorylation in response to GH has been shown to be modestly prolonged in SOCS-2^{-/-} primary hepatocytes compared with those from wild type mice, and much of the acceleration of growth in SOCS-2^{-/-} mice requires the presence of STAT5b, a key mediator of GH action (Greenhalgh *et al.*,
5
10 *Molecular Endocrinology* 16(6): 1394-1406, 2002).

All cellular responses to CSFs are the consequence of signals arising from the cytoplasmic domain of the CSF receptor (CSFR), after ligation of the extracellular domain of the receptor by a CSF. Granulocyte-colony stimulating factor (G-CSF) is an example of a CSF
15 involved in a range of physiological processes such as inflammation and stem and progenitor cell mobilization. It is an essential regulator of normal neutrophil production and survival. Pharmacological therapy with recombinant human G-CSF is widely clinically used to accelerate neutrophil recovery after chemotherapy or hemopoietic stem cell transplantation, and to reduce the risk of development of life-threatening infections in these
20 settings. G-CSF mediates its effects *via* its receptor, G-CSFR (Avalos, *Blood* 88(3): 761-777, 1996).

Ligation of the extracellular domain of the G-CSFR results in activation of multiple intracellular signaling cascades, some of which rely on phosphorylation of one or more of
25 four tyrosine residues in the C-terminal region of the receptor. JAK1, JAK2 and TYK2 are tyrosine kinases recruited to the receptor, and these in turn activate STAT1, STAT3 and STAT5, among other signaling intermediates (Nicholson *et al.*, *Proc. Natl. Acad. Sci. USA* 91(8): 2985-2988, 1994; Tian *et al.*, *Blood* 84(6): 1760-1764, 1994; Tian *et al.*, *Blood* 88(12): 4435-4444, 1996; de Koning *et al.*, *Blood* 87(4): 1335-1342, 1996; Ward *et al.*,
30 *Blood* 93(1): 113-124, 1999).

- 4 -

Although it has been suspected that SOCS molecules and in particular SOCS-3 may have a role in regulating G-CSF, until the advent of the present invention, the importance of the SOCS molecule's involvement was unclear. For example, SOCS-3 expression is induced
5 in primary myeloid cells when stimulated with G-CSF (Starr *et al.*, *Nature* 387(6636): 917-921, 1997; Hortner *et al.*, *J. Immunol.* 169(3): 1219-1927, 2002).

Furthermore, in cell-based over-expression systems, binding of SOCS-3 to G-CSFR inhibits STAT-dependent gene expression after stimulation of the cell with G-CSF
10 (Hortner *et al.*, 2002, *supra*). However, results derived from such over-expression systems are unreliable predictors of physiological processes. Examining cellular responses to G-CSF in the presence or absence of SOCS proteins such as SOCS-3 is a true test system enabling definition of the ability of modulators of SOCS-3 activity as regulators of G-CSF-induced responses.

15

- 5 -

SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the
5 inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Nucleotide and amino acid sequences are referred to by a sequence identifier number (SEQ ID NO:). The SEQ ID NOs: correspond numerically to the sequence identifiers <400>1
10 (SEQ ID NO:1), <400>2 (SEQ ID NO:2), etc. A summary of the sequence identifiers is provided in Table 1. A sequence listing is provided at the end of the specification.

Abbreviations used herein are defined in Table 2.

- 15 The present invention identifies a drug target useful in modulating CSF and in particular G-CSF-induced cellular processes. The instant invention is predicated in part on the identification of SOCS-3 as a key regulator of G-CSF intracellular signaling. The present invention enables, therefore, rational drug design or screening of natural product or chemical libraries for compounds which modulate the responses of cells to G-CSF.
- 20 Enhancement of G-CSF-signaling is proposed to be useful in facilitating neutrophil recovery after myelosuppressive chemotherapy, radiotherapy or chemoradiotherapy, inducing mobilization of stem and progenitor cells and in the treatment of prophylaxis of bacterial, viral or fungal infection or recovery therefrom.
- 25 Down-regulation of G-CSF-signaling such as following administration of agonists of SOCS-3 is proposed to be useful in reducing unwanted clinical sequelae of inflammatory processes characterized by neutrophil accumulation and activation. Examples of such clinical sequelae include engraftment syndrome following allogeneic or autologous stem cell transplantation, pulmonary inflammation such as observed after recovery from
30 neutropenia, acute arthritis, inflammatory bowel disease and Sweets syndrome.

- 6 -

The compounds of the present invention may be chemical molecules, peptides, polypeptides or proteins, or genetic molecules including nucleic acid molecules (such as sense and antisense molecules), RNAi or siRNA or complexes containing same. The
5 compounds may also be formulated into a range of compositions.

The compounds of the present invention may be used to treat animals including mammalian animals such as human subjects with a range of G-CSF-mediated physiological conditions such as those listed above.
10

The present invention further provides methods for identifying compounds which up-or down-regulate G-CSF-signaling.

A summary of sequence identifiers used throughout the subject specification is provided in Table 1.

TABLE 1

5 *Summary of sequence identifiers*

SEQUENCE ID NO:	DESCRIPTION
1	Nucleotide sequence encoding human SOCS-3
2	Amino acid sequence of human SOCS-3
3	Nucleotide sequence of mouse SOCS-3
4	Amino acid sequence of mouse SOCS-3

- 8 -

TABLE 2***Abbreviations***

ABBREVIATION	DESCRIPTION
CSF	colony stimulating factor
G-CSF	granulocyte-colony stimulating factor
JAK	Janus kinase
SOCS	suppressor of cytokine signaling
SOCS Box	conserved C-terminal region of SOCS molecule which recruits ubiquitin ligases
STAT	signal transducer and activators of transcription
CIS	cytokine-inducible SH2
IGF-I	insulin-like growth factor-I
GH	growth hormone
MUP	major urinary protein
CSFR	colony stimulating factor receptor
G-CSFR	granulocyte-stimulating factor receptor
bHLH	basic helix-loop-helix gene
BM	bone marrow
SOCS-3 ⁻	null mutation in SOCS-3 allele
SOCS-3 ^{fl}	LoxP-flanked conditional SOCS-3 allele

BRIEF DESCRIPTION OF THE FIGURES

Figures 1 and 2 are photographic representations showing that hemopoietic cells from VavCre⁺ SOCS-3^{-fl} mice are SOCS-3-deficient. DNA from bone marrow (BM), thymus, spleen and lymph nodes of VavCre⁺ SOCS^{+/fl}, VavCre⁺ SOCS-3^{-fl} or VavCre⁻ SOCS-3^{+/fl} mice was extracted. In Figure 1, Southern blotting reveals efficient deletion of the floxed (fl) allele with conversion to the Δ allele in all tissues examined. In Figure 2, PCR on DNA from sub-fractionated BM cells was performed and the products revealed after electrophoresis in an ethidium-containing gel.

10

Figure 3 is a graphical representation showing increased frequency of G-CSF-responsive CFC in SOCS-3-deficient bone marrow. 25,000 bone marrow cells, either SOCS-3 deficient or control were cultured with specific stimuli in supramaximal concentration for seven days. Mean $\pm$ SD of results from 4-6 mice per genotype. * p<0.01. Control mice had at least one functional SOCS-3 allele, i.e. genotype +/fl or +/ Δ .

15

Figure 4 is a graphical representation showing increased colony size in SOCS-3-deficient bone marrow stimulated by G-CSF and IL-6. 25,000 bone marrow cells, either SOCS-3-deficient or wild-type were cultured with specific stimuli in supramaximal concentrations for seven days, then individual colonies were picked, pooled and counted. Mean $\pm$ SD of results from 2-3 experiments. *p<0.01.

20

Figure 5 is a graphical representation showing enhanced proliferation of SOCS-3-deficient Gr-1⁺ myeloid cells in response to G-CSF but not IL-3. 100,000 GR-1⁺ bone marrow cells, either SOCS-3-deficient or SOCS-3-sufficient were cultured with either G-CSF or IL-3 in various concentrations for 48 hours. Tritiated thymidine was then added and the cultures continued for a further 16 hours prior to analysis of thymidine incorporation. Mean $\pm$ SD of results of triplicate cultures per genotype.

25

- 10 -

Figure 6 is a graphical representation showing enhanced *in vivo* responses induced by G-CSF in VavCre⁺ SOCS^{-fl} mice. Mice were injected with G-CSF 2.5 µg twice daily i.p. for four days and analyzed on the fifth day. Progenitors were enumerated by culturing 5-20 µl of blood in standard CFC assays for seven days prior to fixation, staining and counting at 40x magnification. Mean ±SD of results from four mice per group (except vehicle injected VavCre⁺ SOCS^{-fl} mice where n=2). *p<0.01.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compounds which selectively modulate levels or activity of a CSF and in particular G-CSF in animals, such as mammals and in particular humans. The compounds up-regulate or down-regulate intracellular signals induced by G-CSF. The compounds act by modulating levels or the activity of a SOCS molecule involved in inhibiting G-CSF-signaling, such as SOCS-3. Consequently, the present invention provides G-CSF modulators which include compounds which up- or down-regulate the levels or activity of SOCS-3 or other molecules affected by, or which affect, G-CSF activity. The G-CSF-signaling modulators of the present invention include agonists and antagonists of SOCS-3 and are useful in modulating G-CSF-induced physiological processes. For example, up-regulation of G-CSF-induced signaling is proposed to be useful in facilitating neutrophil recovery after myelosuppressive chemotherapy, radiotherapy or chemoradiotherapy, inducing mobilization of stem and progenitor cells and in the treatment of prophylaxis of bacterial, viral or fungal infection or recovery therefrom.

Down-regulation of G-CSF-induced signaling such as following administration of agonists of SOCS-3 is proposed to be useful in reducing unwanted clinical sequelae of inflammatory processes characterized by neutrophil accumulation and activation. Examples of such clinical sequelae include engraftment syndrome following allogeneic or autologous stem cell transplantation, pulmonary inflammation such as observed after recovery from neutropenia, acute arthritis, inflammatory bowel disease and Sweets syndrome.

Before describing the present invention in detail, it is to be understood that unless otherwise indicated, the subject invention is not limited to specific formulation components, manufacturing methods, dosage regimens, or the like, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

It must be noted that, as used in the subject specification, the singular forms "a", "an" and

- 12 -

“the” include plural aspects unless the context clearly dictates otherwise. Thus, for example, reference to a “compound” includes a single compound, as well as two or more compounds; reference to “an agonist” or “antagonist” includes a single agonist or antagonist as well as two or more agonists or antagonists, and so forth.

5

In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set forth below.

10 The terms “compound”, “agonist”, “antagonist”, “active agent”, “pharmacologically active agent”, “medicament”, “active” and “drug” are used interchangeably herein to refer to a chemical compound that induces a desired pharmacological and/or physiological effect such a up- or down-regulating G-CSF-induced signaling or ameliorating the symptoms of elevated or reduced levels of G-CSF. The terms also encompass pharmaceutically acceptable and pharmacologically active ingredients of those active agents specifically
15 mentioned herein including but not limited to salts, esters, amides, prodrugs, active metabolites, analogs and the like. When the terms “compound”, “agonist”, antagonist”, “active agent”, “pharmacologically active agent”, “medicament”, “active” and “drug” are used, then it is to be understood that this includes the active agent *per se* as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, prodrugs,
20 metabolites, analogs, etc. The term “compound” is not to be construed as a chemical compound only but extends to peptides, polypeptides and proteins as well as genetic molecules such as RNA, DNA and chemical analogs thereof as well as RNAi- or siRNA-type molecules or complexes comprising same. Reference to “RNA” and “DNA” includes oligonucleotide RNA or DNA molecules as well as sense, antisense or double-stranded
25 forms.

The present invention contemplates, therefore, compounds useful in up- or down-regulating G-CSF signaling *via* modulation of a SOCS molecule such as SOCS-3. One group of compounds acts as SOCS-3 antagonists which have the effect of up-regulating G-
30 CSF signaling. Another group of compounds are SOCS-3 agonists which down-regulate G-

- 13 -

CSF signaling. Yet another group of compounds affect gene expression of the SOCS-3 gene.

By the terms "effective amount" or "therapeutically effective amount" of an agent as used
5 herein are meant a sufficient amount of the agent to provide the desired therapeutic or
physiological effect. Furthermore, an "effective G-CSF modulating amount" of an agent is
a sufficient amount of the agent to directly or indirectly reduce or elevate the levels of G-
CSF-induced intracellular signaling. Indirect modulation in G-CSF induced intracellular
10 signaling is conveniently achieved by up- or down-regulating SOCS-3 or providing a
SOCS-3 equivalent or mimetic. Of course, undesirable effects, e.g. side effects, are
sometimes manifested along with the desired therapeutic effect; hence, a practitioner
balances the potential benefits against the potential risks in determining what is an
appropriate "effective amount". The exact amount required will vary from subject to
15 subject, depending on the species, age and general condition of the subject, mode of
administration and the like. Thus, it may not be possible to specify an exact "effective
amount". However, an appropriate "effective amount" in any individual case may be
determined by one of ordinary skill in the art using only routine experimentation.

By "pharmaceutically acceptable" carrier excipient or diluent is meant a pharmaceutical
20 vehicle comprised of a material that is not biologically or otherwise undesirable, i.e. the
material may be administered to a subject along with the selected active agent without
causing any or a substantial adverse reaction. Carriers may include excipients and other
additives such as diluents, detergents, coloring agents, wetting or emulsifying agents, pH
buffering agents, preservatives, and the like.

25 Similarly, a "pharmacologically acceptable" salt, ester, amide, prodrug or derivative of a
compound as provided herein is a salt, ester, amide, prodrug or derivative that is not
biologically or otherwise undesirable.

30 The terms "treating" and "treatment" as used herein refer to reduction in severity and/or

- 14 -

frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage. Thus, for example, "treating" a patient involves prevention of a particular disorder or adverse physiological event in a susceptible individual as well as
5 treatment of a clinically symptomatic individual by inhibiting or causing regression of a disorder or disease. Thus, for example, the present method of "treating" a patient in need of therapy of conditions involving G-CSF-induced physiological processes encompasses both prevention of a condition, disease or disorder as well as treating the condition, disease or disorder. In any event, the present invention contemplates the treatment or prophylaxis of
10 any condition requiring the up- or down-regulation of G-CSF-induced intracellular signaling and hence activity. Up-regulation of G-CSF-induced responses is proposed to be useful in facilitating neutrophil recovery after myelosuppressive chemotherapy, radiotherapy or chemoradiotherapy, inducing mobilization of stem and progenitor cells and in the treatment of prophylaxis of bacterial, viral or fungal infection or recovery therefrom.

15 Down-regulation of G-CSF-induced responses such as following administration of agonists of SOCS-3 is proposed to be useful in reducing unwanted clinical sequelae of inflammatory processes characterized by neutrophil accumulation and activation. Examples of such clinical sequelae include engraftment syndrome following allogenic or autologous stem cell transplantation, pulmonary inflammation such as observed after recovery from
20 neutropenia, acute arthritis, inflammatory bowel disease and Sweets syndrome.

The present invention contemplates autologous therapy involving the removal of stem or progenitor cells, subjecting same to proliferation conditions, genetic manipulation or other
25 physiological stimulus and then returning the cells to the same or a compatible subject in the presence of a compound of the present invention which facilitates mobilization of stem or progenitor cells. Autologous therapy is a form of treating a patient or subject.

"Patient" as used herein refers to an animal, preferably a mammal preferably a higher or
30 lower primate and most preferably a human who can benefit from the pharmaceutical

- 15 -

formulations and methods of the present invention. There is no limitation on the type of animal that could benefit from the presently described pharmaceutical formulations and methods. A patient regardless of whether a human or non-human animal may be referred to as an individual, subject, animal, host or recipient.

5

The compounds of this aspect of the present invention may be large or small molecules, nucleic acid molecules (including antisense or sense molecules) such as mRNA, cDNA, siRNA or RNAi, peptides, polypeptides or proteins or hybrid molecules such as RNAi- or siRNA-complexes, ribozymes or DNazymes.

10

The preferred animals are humans or other primates, lower primates, livestock animals, laboratory test animals, companion animals or captive wild animals.

Examples of non-human primates include baboons and marmosets.

15

Examples of laboratory test animals include mice, rats, rabbits, guinea pigs and hamsters. Rabbits and rodent animals, such as rats and mice, provide a convenient test system or animal model as do primates and lower primates. Livestock animals include sheep, cows, pigs, goats, horses and donkeys. Non-mammalian animals such as zebrafish and amphibians (including cane toads) are also contemplated.

20

The present invention provides, therefore, drugs which inhibit or promote G-CSF activity by up-or down-regulating SOCS-3 activity or SOCS-3 gene expression.

25

The present invention contemplates, therefore, methods of screening for drugs comprising, for example, contacting a candidate drug with a G-CSF regulator molecule (e.g. SOCS-3) or a fragment thereof or a nucleic acid molecule encoding same. These molecules are referred to herein as "targets", "a target" or "target molecule". The screening procedure includes assaying (i) for the presence of a complex between the drug and the target, or (ii) an alteration in the expression levels of nucleic acid molecules encoding the target. One

30

- 16 -

form of assay involves competitive binding assays. In such competitive binding assays, the target is typically labeled. Free target is separated from any putative complex and the amount of free (i.e. uncomplexed) label is a measure of the binding of the agent being tested to target molecule. One may also measure the amount of bound, rather than free,
5 target. It is also possible to label the compound rather than the target and to measure the amount of compound binding to target in the presence and in the absence of the drug being tested.

Another technique for drug screening provides high throughput screening for compounds
10 having suitable binding affinity to a target and is described in detail in Geysen (International Patent Publication No. WO 84/03564). Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with a target and washed. Bound target molecule is then detected by methods well known in the art. This
15 method may be adapted for screening for non-peptide, chemical entities. This aspect, therefore, extends to combinatorial approaches to screening for target antagonists or agonists.

Purified target can be coated directly onto plates for use in the aforementioned drug
20 screening techniques. However, non-neutralizing antibodies to the target may also be used to immobilize the target on the solid phase.

The present invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of specifically binding the target compete with a test
25 compound for binding to the target or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants of the target.

The above screening methods are particularly useful for screening for agents which interact
30 with SOCS-3 and up- or -down-regulate activity or gene expression.

- 17 -

The present invention contemplates, therefore, any compound which inhibits G-CSF signaling within cells and which, therefore, modulates cellular responses to G-CSF.

- 5 Accordingly, one aspect of the present invention provides an isolated compound which inhibits or elevates G-CSF-induced responses.

As stated above, the present invention is also useful for screening for other compounds which up-regulates expression of a gene encoding SOCS-3, or which mimic SOCS-3
10 activity. Such targets may be used in any of a variety of drug screening techniques, such as those described herein and in International Publication No. WO 97/02048.

A target antagonist or agonist includes a variant of the target molecule. In one embodiment, the target is a polypeptide. The term "polypeptide" refers to a polymer of amino acids and
15 its equivalent and does not refer to a specific length of the product, thus, peptides, oligopeptides and proteins are included within the definition of a polypeptide. This term also does not exclude modifications of the polypeptide, for example, glycosylations, acylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example,
20 unnatural amino acids, etc.), polypeptides with substituted linkages as well as other modifications known in the art, both naturally and non-naturally occurring. Ordinarily, such polypeptides will be at least about 40% similar to the natural target sequence, preferably in excess of 90% and more preferably at least about 95% similar. Also included are proteins encoding by DNAs which hybridize under high or low stringency conditions to
25 target-encoding nucleic acids and closely related polypeptides or proteins retrieved by antisera to a target molecule protein.

Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein and may be designed to modulate one or more properties of
30 the polypeptide such as stability against proteolytic cleavage without the loss of other

- 18 -

functions or properties. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues involved. Preferred substitutions are ones which are conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and tyrosine, phenylalanine.

Certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules or binding sites on proteins interacting with the target. Since it is the interactive capacity and nature of a protein which defines that protein's biological functional activity, certain amino acid substitutions can be made in a protein sequence and its underlying DNA coding sequence and nevertheless obtain a protein with like properties. In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydrophobic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte and Doolittle, *J. Mol. Biol.* 157: 105-132, 1982). Alternatively, the substitution of like amino acids can be made effectively on the basis of hydrophilicity. The importance of hydrophilicity in conferring interactive biological function of a protein is generally understood in the art (U.S. Patent No. 4,554,101). The use of the hydrophobic index or hydrophilicity in designing polypeptides is further discussed in U.S. Patent No. 5,691,198.

The length of the polypeptide sequences compared for homology will generally be at least about 16 amino acids, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues and preferably more than about 35 residues.

The nucleotide sequence encoding SOCS-3 is set forth in SEQ ID NOs:1 and 2, respectively for human SOCS-3 and SEQ ID NOs:3 and 4, respectively for mouse SOCS-3.

- 19 -

- The polypeptide sequences for SOCS-3 are set forth in SEQ ID NO:2 (murine) and SEQ ID NO:4 (human). Full length polypeptides, or parts thereof, may be used in accordance with the present invention to identify agonists or antagonists of SOCS-3 expression or activity.
- 5 Preferred polypeptides include the polypeptides set forth in SEQ ID NO:2 and SEQ ID NO:4, and polypeptides comprising the SH₂ domain of SOCS-3 (amino acids 45 to 127 of SEQ ID NO:2 and amino acids 45 to 127 of SEQ ID NO:4) and/or the SOCS-box motif (amino acids 186 to 221 of SEQ ID NO:2 and amino acids 186 to 221 of SEQ ID NO:4).
- 10 The nucleotide sequences corresponding to the SH₂ domain and SOCS-box motif are nucleotides 133 to 381 and 556 to 663 of SEQ ID NO:1 and 150 to 398 and 572 to 680 of SEQ ID NO:3. Preferred nucleotide sequences of the present invention include the nucleotide sequences set forth in SEQ ID NO:1 and SEQ ID NO:3 and nucleotide sequences comprising nucleotides 133 to 381 and/or 556 to 663 of SEQ ID NO:1 and 150
- 15 to 398 and/or 572 to 680 of SEQ ID NO:3.

The present invention further contemplates chemical analogs of the target molecules. Again, these are generally antagonistic or agonistic to target activity.

- 20 Analogs contemplated herein include but are not limited to modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogs.
- 25 Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH₄; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino

- 20 -

groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH₄.

The guanidine group of arginine residues may be modified by the formation of heterocyclic
5 condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitization, for example, to a corresponding amide.

10 Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-
15 chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide
20 or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with
25 diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine,
30 ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or

D-isomers of amino acids. A list of unnatural amino acids, contemplated herein is shown in Table 3.

TABLE 3**5 Codes for non-conventional amino acids**

	Non-conventional amino acid	Code	Non-conventional amino acid	Code
10	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
	aminocyclopropane-	Cpro	L-N-methylasparagine	Nmasn
	carboxylate		L-N-methylaspartic acid	Nmasp
15	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbornyl-	Norb	L-N-methylglutamine	Nmgln
	carboxylate		L-N-methylglutamic acid	Nmglu
	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
20	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
25	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
30	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval

- 22 -

	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva
5	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgabv
	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
10	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
15	D- α -methyllleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methylllysine	Dmlys	N-benzylglycine	Nphe
	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
20	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- α -methyltyrosine	Dmtty	N-cyclodecylglycine	Ncdec
25	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
30	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe

- 23 -

	D-N-methylglutamine	Dnmglu	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
5	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmt
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpn
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
10	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- α -naphthylalanine	Nmanap
15	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
20	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mglu	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
25	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
30	L- α -methylserine	Mser	L- α -methylthreonine	Mthr

- 24 -

L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhph
N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
carbamylmethyl)glycine		carbamylmethyl)glycine	
5 1-carboxy-1-(2,2-diphenyl-	Nmbc		
ethylamino)cyclopropane			

Crosslinkers can be used, for example, to stabilize 3D conformations, using homo-
 10 bifunctional crosslinkers such as the bifunctional imido esters having (CH₂)_n spacer groups
 with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional
 reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide
 and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or
 carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for
 15 example, incorporation of C α and N α -methylamino acids, introduction of double bonds
 between C α and C β atoms of amino acids and the formation of cyclic peptides or analogs by
 introducing covalent bonds such as forming an amide bond between the N and C termini,
 between two side chains or between a side chain and the N or C terminus.

20 The terms "peptide mimetic", "target mimetic" or "mimetic" are intended to refer to a
 substance which has some chemical similarity to the target but which antagonizes or
 agonizes or mimics the target. A peptide mimetic may be a peptide-containing molecule
 that mimics elements of protein secondary structure (Johnson *et al.*, "Peptide Turn
 Mimetics" in *Biotechnology and Pharmacy*, Pezzuto *et al.*, Eds., Chapman and Hall, New
 25 York, 1993). The underlying rationale behind the use of peptide mimetics is that the
 peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way
 as to facilitate molecular interactions such as those of antibody and antigen, enzyme and
 substrate or scaffolding proteins. A peptide mimetic is designed to permit molecular
 interactions similar to the natural molecule and, hence, compete for molecules which might
 30 otherwise interact with SOCS-3.

- 25 -

Again, the compounds of the present invention may be selected to interact with a target alone or single or multiple compounds may be used to affect multiple targets.

- 5 The target polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, or borne on a cell surface. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant polynucleotides expressing the polypeptide or fragment, preferably in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays.
- 10 One may measure, for example, the formation of complexes between a target or fragment and the agent being tested, or examine the degree to which the formation of a complex between a target or fragment and a known ligand is aided or interfered with by the agent being tested.
- 15 A substance identified as a modulator of target function or gene activity may be a peptide or non-peptide in nature. Non-peptide "small molecules" are often preferred for many *in vivo* pharmaceutical uses. Accordingly, a mimetic or mimic of the substance (particularly if a peptide) may be designed for pharmaceutical use.
- 20 The designing of mimetics to a pharmaceutically active compound is a known approach to the development of pharmaceuticals based on a "lead" compound. This might be desirable where the active compound is difficult or expensive to synthesize or where it is unsuitable for a particular method of administration, e.g. peptides are unsuitable active agents for oral compositions as they tend to be quickly degraded by proteases in the alimentary canal.
- 25 Mimetic design, synthesis and testing is generally used to avoid randomly screening large numbers of molecules for a target property.

There are several steps commonly taken in the design of a mimetic from a compound having a given target property. First, the particular parts of the compound that are critical and/or important in determining the target property are determined. In the case of a peptide,

30

- 26 -

this can be done by systematically varying the amino acid residues in the peptide, e.g. by substituting each residue in turn. Alanine scans of peptides are commonly used to refine such peptide motifs. These parts or residues constituting the active region of the compound are known as its "pharmacophore".

5

Once the pharmacophore has been found, its structure is modeled according to its physical properties, e.g. stereochemistry, bonding, size and/or charge, using data from a range of sources, e.g. spectroscopic techniques, x-ray diffraction data and NMR. Computational analysis, similarity mapping (which models the charge and/or volume of a pharmacophore,
10 rather than the bonding between atoms) and other techniques can be used in this modeling process.

In a variant of this approach, the three-dimensional structure of the ligand and its binding partner are modeled. This can be especially useful where the ligand and/or binding partner
15 change conformation on binding, allowing the model to take account of this in the design of the mimetic. Modeling can be used to generate inhibitors which interact with the linear sequence or a three-dimensional configuration.

A template molecule is then selected onto which chemical groups which mimic the
20 pharmacophore can be grafted. The template molecule and the chemical groups grafted onto it can conveniently be selected so that the mimetic is easy to synthesize, is likely to be pharmacologically acceptable, and does not degrade *in vivo*, while retaining the biological activity of the lead compound. Alternatively, where the mimetic is peptide-based, further stability can be achieved by cyclizing the peptide, increasing its rigidity. The mimetic or
25 mimetics found by this approach can then be screened to see whether they have the target property, or to what extent they exhibit it. Further optimization or modification can then be carried out to arrive at one or more final mimetics for *in vivo* or clinical testing.

The goal of rational drug design is to produce structural analogs of biologically active
30 polypeptides of interest or of small molecules with which they interact (e.g. agonists,

- 27 -

antagonists, inhibitors or enhancers) in order to fashion drugs which are, for example, more active or stable forms of the polypeptide, or which, e.g. enhance or interfere with the function of a polypeptide *in vivo*. See, e.g. Hodgson (*Bio/Technology* 9: 19-21, 1991). In one approach, one first determines the three-dimensional structure of a protein of interest
5 (i.e. G-CSF or SOCS-3) by x-ray crystallography, by computer modeling or most typically, by a combination of approaches. Useful information regarding the structure of a polypeptide may also be gained by modeling based on the structure of homologous proteins. An example of rational drug design is the development of HIV protease inhibitors (Erickson *et al.*, *Science* 249: 527-533, 1990). In addition, target molecules may be
10 analyzed by an alanine scan (Wells, *Methods Enzymol.* 202: 2699-2705, 1991). In this technique, an amino acid residue is replaced by Ala and its effect on the peptide's activity is determined. Each of the amino acid residues of the peptide is analyzed in this manner to determine the important regions of the peptide.

15 It is also possible to isolate a target-specific antibody, selected by a functional assay and then to solve its crystal structure. In principle, this approach yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of
20 the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced banks of peptides. Selected peptides would then act as the pharmacore.

Two-hybrid screening is also useful in identifying other members of a biochemical or
25 genetic pathway associated with a target. Two-hybrid screening conveniently uses *Saccharomyces cerevisiae* and *Saccharomyces pombe*. Target interactions and screens for inhibitors can be carried out using the yeast two-hybrid system, which takes advantage of transcriptional factors that are composed of two physically separable, functional domains. The most commonly used is the yeast GAL4 transcriptional activator consisting of a DNA
30 binding domain and a transcriptional activation domain. Two different cloning vectors are

- 28 -

used to generate separate fusions of the GAL4 domains to genes encoding potential binding proteins. The fusion proteins are co-expressed, targeted to the nucleus and if interactions occur, activation of a reporter gene (e.g. *lacZ*) produces a detectable phenotype. In the present case, for example, *S. cerevisiae* is co-transformed with a library or vector
5 expressing a cDNA GAL4 activation domain fusion and a vector expressing a G-CSF-GAL4 or SOCS-3-GAL4 binding domain fusion. If *lacZ* is used as the reporter gene, co-expression of the fusion proteins will produce a blue color. Small molecules or other candidate compounds which interact with a target will result in loss of color of the cells. This system can be used to screen for small molecules that inhibit the target function of
10 targets such as SOCS-3. Reference may be made to the yeast two-hybrid systems as disclosed by Munder *et al.* (*Appl. Microbiol. Biotechnol.* 52(3): 311-320, 1999) and Young *et al.*, *Nat. Biotechnol.* 16(10): 946-950, 1998). Molecules thus identified by this system are then re-tested in animal cells. A similar approach may also be used to locate agonists of SOCS-3.

15

The present invention extends to a genetic approach for up- or down-regulating SOCS-3 levels or activity. In one example, nucleic acid molecules which encode SOCS-3 or which are used to up- or down-regulate the genes encoding SOCS-3 are introduced to cells.

20 The terms "nucleic acids", "nucleotide" and "polynucleotide" include RNA, cDNA, genomic DNA, synthetic forms and mixed polymers, both sense and antisense strands, and may be chemically or biochemically modified or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the
25 naturally occurring nucleotides with an analog (such as the morpholine ring), internucleotide modifications such as uncharged linkages (e.g. methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.), charged linkages (e.g. phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g. polypeptides), intercalators (e.g. acridine, psoralen, etc.), chelators, alkylators and modified linkages (e.g.
30 α -anomeric nucleic acids, etc.). Also included are synthetic molecules that mimic

- 29 -

polynucleotides in their ability to bind to a designated sequence *via* hydrogen binding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

5

Antisense polynucleotide sequences, for example, are useful in preventing or diminishing the expression of a genetic sequence or locus encoding SOCS-3. The nucleotide sequence encoding human SOCS-3 is set forth in SEQ ID NO:1. An example of a homolog is murine SOCS-3 which is encoded by SEQ ID NO:3. Polynucleotide vectors, for example,
10 containing all or a portion of a target SOCS-3 locus may be placed under the control of a promoter in an antisense orientation and introduced into a cell. Expression of such an antisense construct within a cell will interfere with target transcription and/or translation. Furthermore, co-suppression and mechanisms to induce RNAi or siRNA may also be employed. Such techniques may be useful to inhibit genes which encode or promote
15 SOCS-3 gene expression. Alternatively, antisense or sense molecules may be directly administered. In this latter embodiment, the antisense or sense molecules may be formulated in a composition and then administered by any number of means to target cells.

A variation on antisense and sense molecules involves the use of morpholinos, which are
20 oligonucleotides composed of morpholine nucleotide derivatives and phosphorodiamidate linkages (for example, Summerton and Weller, *Antisense and Nucleic Acid Drug Development* 7: 187-195, 1997). Such compounds are injected into embryos and the effect of interference with mRNA is observed.

25 In one embodiment, the present invention employs compounds such as oligonucleotides and similar species for use in modulating the function or effect of nucleic acid molecules encoding SOCS-3, i.e. the oligonucleotides induce transcriptional or post-transcriptional gene silencing. This is accomplished by providing oligonucleotides which specifically hybridize with one or more nucleic acid molecules encoding SOCS-3. The oligonucleotides
30 may be provided directly to a cell or generated within the cell. As used herein, the terms

- 30 -

“target nucleic acid” and “nucleic acid molecule encoding SOCS-3” have been used for convenience to encompass DNA encoding G-CSF or SOCS-3, RNA (including pre-mRNA and mRNA or portions thereof) transcribed from such DNA, and also cDNA derived from such RNA. The hybridization of a compound of the subject invention with its target nucleic acid is generally referred to as “antisense”. Consequently, the preferred mechanism believed to be included in the practice of some preferred embodiments of the invention is referred to herein as “antisense inhibition.” Such antisense inhibition is typically based upon hydrogen bonding-based hybridization of oligonucleotide strands or segments such that at least one strand or segment is cleaved, degraded, or otherwise rendered inoperable. In this regard, it is presently preferred to target specific nucleic acid molecules and their functions for such antisense inhibition.

The functions of DNA to be interfered with can include replication and transcription. Replication and transcription, for example, can be from an endogenous cellular template, a vector, a plasmid construct or otherwise. The functions of RNA to be interfered with can include functions such as translocation of the RNA to a site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more RNA species, and catalytic activity or complex formation involving the RNA which may be engaged in or facilitated by the RNA. One preferred result of such interference with target nucleic acid function is modulation of the expression of the growth hormone gene. In the context of the present invention, “modulation” and “modulation of expression” mean either an increase (stimulation) or a decrease (inhibition) in the amount or levels of a nucleic acid molecule encoding the gene, e.g., DNA or RNA. Inhibition is often the preferred form of modulation of expression and mRNA is often a preferred target nucleic acid.

In the context of this invention, “hybridization” means the pairing of complementary strands of oligomeric compounds. In the present invention, the preferred mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed

- 31 -

Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleobases) of the strands of oligomeric compounds. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. Hybridization can occur under varying circumstances.

5

An antisense compound is specifically hybridizable when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions
10 in which specific binding is desired, i.e. under physiological conditions in the case of *in vivo* assays or therapeutic treatment, and under conditions in which assays are performed in the case of *in vitro* assays.

“Complementary” as used herein, refers to the capacity for precise pairing between two
15 nucleobases of an oligomeric compound. For example, if a nucleobase at a certain position of an oligonucleotide (an oligomeric compound), is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, said target nucleic acid being a DNA, RNA, or oligonucleotide molecule, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary
20 position. The oligonucleotide and the further DNA, RNA, or oligonucleotide molecule are complementary to each other when a sufficient number of complementary positions in each molecule are occupied by nucleobases which can hydrogen bond with each other. Thus, “specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number of
25 nucleobases such that stable and specific binding occurs between the oligonucleotide and a target nucleic acid.

According to the present invention, compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides,
30 alternate splicers, primers, probes, and other oligomeric compounds which hybridize to at

- 32 -

least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges or loops. Once introduced to a system, the compounds of the invention may elicit the action of one or more enzymes or structural proteins to effect modification of the target nucleic acid. One non-limiting example of such an enzyme is RNase H, a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. It is known in the art that single-stranded antisense compounds which are "DNA-like" elicit RNase H. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression. Similar roles have been postulated for other ribonucleases such as those in the RNase III and ribonuclease L family of enzymes.

While the preferred form of antisense compound is a single-stranded antisense oligonucleotide, in many species the introduction of double-stranded structures, such as double-stranded RNA (dsRNA) molecules, has been shown to induce potent and specific antisense-mediated reduction of the function of a gene or its associated gene products. This phenomenon occurs in both plants and animals.

In the context of the subject invention, the term "oligomeric compound" refers to a polymer or oligomer comprising a plurality of monomeric units. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics, chimeras, analogs and homologs thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a target nucleic acid and increased stability in the presence of nucleases.

- 33 -

While oligonucleotides are a preferred form of the compounds of this invention, the present invention comprehends other families of compounds as well, including but not limited to oligonucleotide analogs and mimetics such as those herein described.

5 The compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). One of ordinary skill in the art will appreciate that the invention embodies compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60,
10 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases in length. Although 80 nucleobases is given as an upper range, any length from 8 to the full length gene transcript may be provided.

The open reading frame (ORF) or "coding region" which is known in the art to refer to the
15 region between the translation initiation codon and the translation termination codon, is a region which may be targeted effectively. Within the context of the present invention, one region is the intragenic region encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene.

20 Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA (or corresponding nucleotides on the gene), and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the
25 translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA (or corresponding nucleotides on the gene). The 5' cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA *via* a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides
30 adjacent to the cap site. It is also preferred to target the 5' cap region.

- 34 -

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as “introns”, which are excised from a transcript before it is translated. The remaining (and, therefore, translated) regions are known as “exons” and are
5 spliced together to form a continuous mRNA sequence. Targeting splice sites, i.e. intron-exon junctions or exon-intron junctions, may also be particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred target sites. mRNA transcripts produced *via* the process of
10 splicing of two (or more) mRNAs from different gene sources are known as “fusion transcripts”. It is also known that introns can be effectively targeted using antisense compounds targeted to, for example, DNA or pre-mRNA.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the
15 nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides,
20 the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric compound can be further joined to form a circular compound, however, linear compounds are generally preferred. In addition, linear compounds may have internal nucleobase complementarity and may, therefore, fold in a manner as to produce a fully or partially double-stranded
25 compound. Within oligonucleotides, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include
30 oligonucleotides containing modified backbones or non-natural internucleoside linkages.

- 35 -

As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones containing a phosphorus atom therein include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

20

In an alternative embodiment, genetic constructs including DNA vaccines are used to generate antisense molecules *in vivo*. Furthermore, many of the preferred features described above are appropriate for sense nucleic acid molecules or for gene therapy applications to promote SOCS-3 gene expression. For example, genetic constructs may be administered which generate elevated levels of SOCS-3.

25

Following identification of a substance which modulates SOCS-3 activity or gene expression, it may be manufactured and/or used in a preparation, i.e. in the manufacture or formulation or a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals in a method of treatment or prophylaxis or

30

- 36 -

regenerative therapy. Alternatively, they may be incorporated into a patch or slow release capsule or implant.

Thus, the present invention extends, therefore, to a pharmaceutical composition,
5 medicament, drug or other composition including a patch or slow release formulation comprising an agonist or antagonist of target activity or gene expression. Another aspect of the present invention contemplates a method comprising administration of such a composition to a patient such as for treatment or prophylaxis of a range of G-CSF-induced cellular responses. Up-regulation of G-CSF-induced signaling is proposed to be useful in
10 facilitating neutrophil recovery after myelosuppressive chemotherapy, radiotherapy or chemoradiotherapy, inducing mobilization of stem and progenitor cells and in the treatment of prophylaxis of bacterial, viral or fungal infection or recovery therefrom.

Down-regulation of G-CSF such as following administration of agonists of SOCS-3
15 proposed to be useful in reducing unwanted clinical sequelae of inflammatory processes characterized by neutrophil accumulation and activation. Examples of such clinical sequelae include engraftment syndrome following allogenic or autologous stem cell transplantation, pulmonary inflammation such as observed after recovery from neutropenia, acute arthritis, inflammatory bowel disease and Sweets syndrome. The compounds of the
20 present invention may also be used in the manufacture of a medicament for the treatment or prophylaxis of a G-CSF-induced cellular response. Furthermore, the present invention contemplates a method of making a pharmaceutical composition comprising admixing a compound of the instant invention with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients. Where multiple compositions are provided, then
25 such compositions may be given simultaneously or sequentially. Sequential administration includes administration within nanoseconds, seconds, minutes, hours or days. Preferably, within seconds or minutes.

Accordingly, another aspect of the present invention contemplates a method for the
30 treatment or prophylaxis of a G-CSF-induced cellular response in an animal, said method

- 37 -

comprising administering to said animal an effective amount of a compound as described herein or a composition comprising same.

Preferably, the animal is a mammal such as a human or other primate or lower primate or
5 laboratory test animal such as a mouse, rat, rabbit, guinea pig, hamster, zebrafish or amphibian.

According to the present invention, a method is also provided of supplying wild-type or mutant target gene function to a cell. This is particularly useful when generating an animal
10 model. Alternatively, it may be part of a gene therapy approach. A target gene or a part of the gene may be introduced into the cell in a vector such that the gene remains extrachromosomal. In such a situation, the gene will be expressed by the cell from the extrachromosomal location. If a gene portion is introduced and expressed in a cell carrying
15 a mutant target allele, the gene portion should encode a part of the target protein. Vectors for introduction of genes both for recombination and for extrachromosomal maintenance are known in the art and any suitable vector may be used. Methods for introducing DNA into cells such as electroporation calcium phosphate co-precipitation and viral transduction are known in the art.

20 Gene transfer systems known in the art may be useful in the practice of genetic manipulation. These include viral and non-viral transfer methods. A number of viruses have been used as gene transfer vectors or as the basis for preparing gene transfer vectors, including papovaviruses (e.g. SV40, Madzak *et al.*, *J. Gen. Virol.* 73: 1533-1536, 1992), adenovirus (Berkner, *Curr. Top. Microbiol. Immunol.* 158: 39-66, 1992; Berkner *et al.*,
25 *BioTechniques* 6: 616-629, 1988; Gorziglia and Kapikian, *J. Virol.* 66: 4407-4412, 1992; Quantin *et al.*, *Proc. Natl. Acad. Sci. USA* 89: 2581-2584, 1992; Rosenfeld *et al.*, *Cell* 68: 143-155, 1992; Wilkinson *et al.*, *Nucleic Acids Res.* 20: 2233-2239, 1992; Stratford-Perricaudet *et al.*, *Hum. Gene Ther.* 1: 241-256, 1990; Schneider *et al.*, *Nature Genetics* 18: 180-183, 1998), vaccinia virus (Moss, *Curr. Top. Microbiol. Immunol.* 158: 25-38,
30 1992; Moss, *Proc. Natl. Acad. Sci. USA* 93: 11341-11348, 1996), adeno-associated virus

- 38 -

(Muzyczka, *Curr. Top. Microbiol. Immunol.* 158: 97-129, 1992; Ohi *et al.*, *Gene* 89: 279-282, 1990; Russell and Hirata, *Nature Genetics* 18: 323-328, 1998), herpesviruses including HSV and EBV (Margolskee, *Curr. Top., Microbiol. Immunol.* 158: 67-95, 1992; Johnson *et al.*, *J. Virol.* 66: 2952-2965, 1992; Fink *et al.*, *Hum. Gene Ther.* 3: 11-19, 1992; 5 Breakefield and Geller, *Mol. Neurobiol.* 1: 339-371, 1987; Freese *et al.*, *Biochem. Pharmacol.* 40: 2189-2199, 1990; Fink *et al.*, *Ann. Rev. Neurosci.* 19: 265-287, 1996), lentiviruses (Naldini *et al.*, *Science* 272: 263-267, 1996), Sindbis and Semliki Forest virus (Berglund *et al.*, *Biotechnology* 11: 916-920, 1993) and retroviruses of avian (Bandyopadhyay and Temin, *Mol. Cell. Biol.* 4: 749-754, 1984; Petropoulos *et al.*, *J. Virol.* 66: 3391-3397, 1992], murine [Miller, *Curr. Top. Microbiol. Immunol.* 158: 1-24, 1992; 10 Miller *et al.*, *Mol. Cell. Biol.* 5: 431-437, 1985; Sorge *et al.*, *Mol. Cell. Biol.* 4: 1730-1737, 1984; Mann and Baltimore, *J. Virol.* 54: 401-407, 1985; Miller *et al.*, *J. Virol.* 62: 4337-4345, 1988] and human [Shimada *et al.*, *J. Clin. Invest.* 88: 1043-1047, 1991; Helseth *et al.*, *J. Virol.* 64: 2416-2420, 1990; Page *et al.*, *J. Virol.* 64: 5270-5276, 1990; 15 Buchschacher and Panganiban, *J. Virol.* 66: 2731-2739, 1982] origin.

Non-viral gene transfer methods are known in the art such as chemical techniques including calcium phosphate co-precipitation, mechanical techniques, for example, microinjection, membrane fusion-mediated transfer *via* liposomes and direct DNA uptake 20 and receptor-mediated DNA transfer. Viral-mediated gene transfer can be combined with direct *in vivo* gene transfer using liposome delivery, allowing one to direct the viral vectors to particular cells. Alternatively, the retroviral vector producer cell line can be injected into particular tissue. Injection of producer cells would then provide a continuous source of vector particles.

25

In an approach which combines biological and physical gene transfer methods, plasmid DNA of any size is combined with a polylysine-conjugated antibody specific to the adenovirus hexon protein and the resulting complex is bound to an adenovirus vector. The trimolecular complex is then used to infect cells. The adenovirus vector permits efficient 30 binding, internalization and degradation of the endosome before the coupled DNA is

- 39 -

damaged. For other techniques for the delivery of adenovirus based vectors, see U.S. Patent No. 5,691,198.

5 Liposome/DNA complexes have been shown to be capable of mediating direct *in vivo* gene transfer. While in standard liposome preparations the gene transfer process is non-specific, localized *in vivo* uptake and expression have been reported in tumor deposits, for example, following direct *in situ* administration.

10 If the polynucleotide encodes a sense or antisense polynucleotide or a ribozyme or DNzyme, expression will produce the sense or antisense polynucleotide or ribozyme or DNzyme. Thus, in this context, expression does not require that a protein product be synthesized. In addition to the polynucleotide cloned into the expression vector, the vector also contains a promoter functional in eukaryotic cells. The cloned polynucleotide sequence is under control of this promoter. Suitable eukaryotic promoters include those
15 described above. The expression vector may also include sequences, such as selectable markers and other sequences described herein.

Cells and animals which carry a mutant target allele (e.g. G-CSF or SOCS-3) or where one or both alleles are deleted can be used as model systems to study the G-CSF-induced
20 cellular responses. Mice, rats, rabbits, guinea pigs, hamsters, zebrafish and amphibians are particularly useful as model systems. A particularly useful insertion is a loxP sequence flanking a target gene which can be excised by cre.

The present invention provides, therefore, a mutation in or flanking a genetic locus
25 encoding a target. The mutation may be an insertion, deletion, substitution or addition to the target-coding sequence or its 5' or 3' untranslated region.

The animal model of the present invention is useful for screening for agents capable of ameliorating or mimicing the effects of a target. In one embodiment, the animal model
30 produces low amounts of a target.

- 40 -

Another aspect of the present invention provides a genetically modified animal wherein said animal produces low amounts of a target relative to a non-genetically modified animal of the same species. Reference to "low amounts" includes zero amounts or up to about
5 10% lower than normalized amounts.

Yet another aspect of the present invention provides multiple (i.e. two or more) genes which are modified.

10 The animal models of the present invention may be in the form of the animals including fish or may be, for example, in the form of embryos for transplantation. The embryos are preferably maintained in a frozen state and may optionally be sold with instructions for use.

The genetically modified animals may also produce larger amounts of a target.

15

Accordingly, another aspect of the present invention is directed to a genetically modified animal over-expressing genetic sequences encoding a target.

A genetically modified animal includes a transgenic animal, or a "knock-out" or "knock-in" animal as well as a conditional deletion mutant. Furthermore, co-suppression may be
20 used to induce post-transcriptional gene silencing. Co-suppression includes administration or induction of RNAi or administration or induction of siRNA or complexes comprising same.

25 The compounds, agents, medicaments, nucleic acid molecules and other target antagonists or agonists of the present invention can be formulated in pharmaceutical compositions which are prepared according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing, Company, Easton, PA, U.S.A.). The composition may contain the active agent or
30 pharmaceutically acceptable salts of the active agent. These compositions may comprise, in

- 41 -

addition to one of the active substances, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The carrier may take a wide variety of forms depending on the form of preparation desired for
5 administration, e.g. intravenous, oral, intrathecal, epineural or parenteral. Systemic administration may involve local or general systemic administration.

For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, powders, suspensions or emulsions. In preparing
10 the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, suspending agents, and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and
15 the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. The active agent can be encapsulated to make it stable to passage through the
20 gastrointestinal tract while at the same time allowing for passage across the blood brain barrier. See for example, International Patent Publication No. WO 96/11698.

For parenteral administration, the compound may be dissolved in a pharmaceutical carrier and administered as either a solution or a suspension. Illustrative of suitable carriers are water,
25 saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative or synthetic origin. The carrier may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like. When the compounds are being administered intrathecally, they may also be dissolved in cerebrospinal fluid.

- 42 -

The active agent is preferably administered in a therapeutically effective amount. The actual amount administered and the rate and time-course of administration will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage, timing, etc. is within the responsibility of general practitioners or
5 specialists and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington's Pharmaceutical Sciences, *supra*.

10 Alternatively, targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibodies or cell specific ligands or specific nucleic acid molecules. Targeting may be desirable for a variety of reasons, e.g. if the agent is unacceptably toxic or if it would otherwise require too high a dosage or if it would not otherwise be able to enter the target cells.

15

Instead of administering these agents directly, they could be produced in the target cell, e.g. in a viral vector such as described above or in a cell based delivery system such as described in U.S. Patent No. 5,550,050 and International Patent Publication Nos. WO 92/19195, WO 94/25503, WO 95/01203, WO 95/05452, WO 96/02286, WO 96/02646,
20 WO 96/40871, WO 96/40959 and WO 97/12635. The vector could be targeted to the target cells. The cell based delivery system is designed to be implanted in a patient's body at the desired target site and contains a coding sequence for the target agent. Alternatively, the agent could be administered in a precursor form for conversion to the active form by an activating agent produced in, or targeted to, the cells to be treated. See, for example,
25 European Patent Application No. 0 425 731A and International Patent Publication No. WO 90/07936.

The present invention is further described by the following non-limiting Examples.

EXAMPLE 1

Generation of mice with SOCS-3-deficient hemopoiesis

Generation of mice bearing null (SOCS-3⁻) and LoxP-flanked conditional (SOCS-3^{fl}) alleles of SOCS-3 have been previously described (Roberts *et al.*, *Proc. Natl. Acad. Sci. USA* 98(16): 9324-9329, 2001; Croker *et al.*, *Nat Immunol.* 4(6): 540-545, 2003) In order to generate mice with SOCS-3-deficient blood cells, transgenic mice were created in which Cre recombinase expression was restricted to cells of the hemopoietic and endothelial lineages (VavCre⁺ mice).

10

A 11.2 kbp plasmid, containing elements of the Vav promoter and a human CD4 reporter was digested with *Sfi I* and *Not I* excising the human CD4 reporter which was then replaced with a nls-Cre (nuclear localization signal-Cre) recombinase cassette (Ogilvy *et al.*, *Blood* 94(6): 1855-1863, 1999). The pIC19H (prokaryotic) sequences were removed by restriction digestion with *Hind III* and the remaining 8.2 kbp fragment was purified from low-melt agarose using agarase (New England Biolabs, USA). The purified DNA was dialyzed for 12 hours in microinjection buffer (10 mM Tris/HCl pH 7.4, 0.1 mM EDTA) and adjusted to 2 µg/mL for microinjection. Eight founders were obtained from 93 potential founders following pronuclear microinjection. Based on the expression of the Vav-Cre transgene in GtROSA26 lacZ reporter mice (Soriano *et al.*, *Nat. Genet.* 21(1): 70-71, 1999), three independent Vav-Cre transgenic lines (15, 48 and 71) were selected to use for intercrossing with mice bearing mutant SOCS-3 alleles.

20

EXAMPLE 2

Clonogenic assays, FACS analyses and tritiated thymidine incorporation assays

25

These were performed exactly as previously described (Alexander *et al.*, *Blood* 87(6): 2162-2170, 1996; Croker *et al.*, *Immunol. Cell Biol.* 80(3): 231-240, 2002).

EXAMPLE 3

In vivo responses to G-CSF

Mice were injected intraperitoneally twice daily with 2.5 µg rhG-CSF (lenograstim). These experiments were performed exactly as previously described except that mice were only injected for four days and analyzed on the fifth day (Roberts *et al.*, *Exp. Hematol.* 22(12): 1156-1163, 1994).

EXAMPLE 4

The VavCre transgene targets Cre recombinase activity to hemopoietic and endothelial cells

To determine the cell-type and tissue-distribution pattern of SOCS-3 deletion to be expected in subsequent experiments, VavCre⁺ mice were intercrossed with Gt-ROSA26lacZ reporter mice and β-galactosidase activity was used as an indicator of Cre-mediated deletion. For each of three lines, high level β-galactosidase expression was observed in all hemopoietic cell lineages and all endothelial cells. β-galactosidase activity was not observed in other adult cell types and tissues including hepatocytes, myocytes, adipocytes, fibroblasts, epithelial cells and renal parenchymal cells. Importantly, β-galactosidase expression was observed in >99% of neutrophils, macrophages, T cells and in greater than 90% of B cells and nucleated erythroid cells.

EXAMPLE 5

Hemopoietic cells from VavCre⁺ SOCS-3^{fl} mice are SOCS-3-deficient

VavCre⁺ SOCS-3^{fl} offspring of matings between VavCre⁺ SOCS-3^{+/-} and SOCS-3^{fl/fl} mice are born in the expected Mendelian proportions, develop normally and are fertile. Genotyping of mature cells from each hemopoietic lineage demonstrated that the SOCS-3^{fl} allele had been deleted in > 95% of cells (Figure 1). VavCre⁺ SOCS-3^Δ hemopoietic cells do not have a functional SOCS-3 allele and are SOCS-3-deficient.

- 45 -

Further, hemopoietic progenitor cells are also uniformly SOCS-3-null as demonstrated by the PCR genotyping shown in Figure 2.

5 **EXAMPLE 6**

Steady-state hemopoiesis is normal in VavCre⁺ SOCS-3^{-fl} mice

The great majority of 6-8 week old adult VavCre⁺ SOCS-3^{-fl} mice display normal peripheral blood counts, bone marrow cellularity and thymic and splenic architecture and
10 cellularity. As outlined in Tables 4 and 5, cellular content of each of these hemopoietic organs is phenotypically normal. A small number (<5%) of VavCre⁺ SOCS-3^{-fl} mice display a neutrophil leukocytosis and splenomegaly.

TABLE 4
*Peripheral blood parameters are normal in VavCre⁺ SOCS-3^{-fl} mice
with SOCS-3 deficient hemopoiesis*

Organ	Genotype	Hct	Platelet (x10 ⁹ /L)	WCC (x10 ⁹ /L)	Differential (x10 ⁹ /L) PMN/MM	Differential (x10 ⁹ /L) Lymph	Differential (x10 ⁹ /L) Mono	Differential (x10 ⁹ /L) Eosin
PB	Control	49 ±1.7	1342±145	6.9±1.9	0.6±0.2	6.6±1.5	0.1±0.3	0±0.1
	VavCre ⁺ SOCS-3 ^{-fl}	46±2.3	1122±306	4.4±1.3	0.7±0.3	3.6±1	0.1±0.1	0.1±0.1

TABLE 5
Normal cellularity of hemopoietic organs in VavCre⁺SOCS-3^{-fl} mice with SOCS-3 deficient hemopoiesis

Organ	Genotype	Cellularity (x10 ⁶)	Weight (mg)	Blast	Pro/Myel	PMN/MM	Lymph	Mono	Eosin	Nuc RBC
	Control					9±3	89±5	3±3	0±1	
PB	VavCre ⁺ SOCS-3 ^{-fl}	4.4±1.9				15±3	83±4	2±2	0±1	
BM	Control	44.3±14		2±1	9±3	23±5	34±6	34±6	2±1	24±2
	VavCre ⁺ SOCS-3 ^{-fl}	37.8±4		2±2	12±2	29±13	25±6	25±9	2±2	23±1
Spleen	Control	110±18	91±13	1±1	1±1	3±2	81±6	81±6		13±3
	VavCre ⁺ SOCS-3 ^{-fl}	137±61	96±34	2±1	3±1	4±1	63±15	63±15		25±13

5 Results represent Mean ± SD or results from 4-6 mice of each genotype. Control mice include VavCre⁺SOCS-3^{+fl} mice and VavCre⁻SOCS-3^{+fl} mice.

EXAMPLE 7***Enhanced G-CSF-induced colony-formation by SOCS-3-deficient bone marrow cells***

5 The total number of myeloid progenitor cells arising from the bone marrow population when maximally stimulated with the combination of SCF plus IL-3 is normal in VavCre⁺ SOCS-3^{-fl} mice. However, a selective increase in the number of clonogenic cells capable of forming colonies in response to G-CSF as a single stimulus was observed. This two-fold increase was specific for G-CSF (Figure 3), and was observed at both supramaximal and
10 submaximal concentrations of G-CSF.

Further, the size of the emergent colonies induced by G-CSF from VavCre⁺ SOCS-3^{-Δ} bone marrow cells was larger than that of colonies grown from control bone marrow cells (Figure 4). Again this was a selective rather than generalized consequence of the loss of
15 SOCS-3, as colony size was normal when cultures were stimulated with most other single cytokines or when combinations were used. However, it was not unique for G-CSF because similarly enhanced colonies were also seen with IL-6.

To investigate whether late onset neutrophilia could be a consequence of the aberrant
20 actions of cytokines on hematopoietic progenitors, we tested the responses of hematopoietic progenitor cells in vitro to a range of hematopoietic growth factors. When maximally stimulated by GM-CSF, M-CSF, IL-3, IL-6, SCF or combinations thereof, the frequency of myeloid progenitor cells arising from the bone marrow of young, healthy mice was normal. However, a selective increase was observed in the number of vavCre⁺SOCS3⁻
25 ^Δ clonogenic cells capable of forming colonies in response to G-CSF (Figure 3). Strikingly, the cellular content of the colonies induced by G-CSF were 2-4 fold greater than for wild-type controls. Again, selectivity was observed for this phenotype, with no changes in the capacity for mature cell generation occurring when the progenitor cells from the same bone marrow sample were stimulated with GM-CSF, M-CSF, SCF, or combinations of these
30 other cytokines. The increased size of the developing colonies was not unique to G-CSF stimulation, however, and was also observed following activation by IL-6.

- 49 -

To reduce the possibility that this two-fold increase in number of G-CSF-responsive progenitors simply reflected enrichment for committed neutrophil progenitors within the bone marrow, cultures of purified lin^-kit^+ progenitor cells were analysed and an increased
5 number of G-CSF-responsive cells, both colony-forming cells and total cells, was again observed. This increased response was observed at both supramaximal and submaximal concentrations of G-CSF.

As well as apparent increased proliferation by SOCS3-deficient progenitor cells stimulated
10 by G-CSF, a subtle shift in differentiation was also evident. There was a significant increase in the number and proportion of macrophages within these colonies, as compared with the nearly exclusively neutrophil composition of colonies derived from wild-type progenitors, with G-CSF-responsive SOCS3-deficient progenitor cells generating
15 macrophage and granulocyte-macrophage colonies in greater proportions than wild-type progenitor cells.

EXAMPLE 8

SOCS-3-deficient myeloid cells are hyper-responsive to G-CSF

20 To exclude the possibility that the above observations trivially reflected aberrant composition of the myeloid progenitor cell pool in VavCre^+ $\text{SOCS-3}^{-/\text{fl}}$ mice, further evidence of enhanced in vitro responses to G-CSF were sought. As stated above, the distribution of morphologically-identifiable myeloid precursors is normal in VavCre^+ $\text{SOCS-3}^{-/\text{fl}}$ mice. Therefore, Gr-1-expressing myeloid cells were collected by fluorescence-
25 activated cell sorting, and their proliferative responses to G-CSF were assayed by tritiated thymidine incorporation. Microscopic analyses of sorted populations confirmed there was no skewing of the composition of the precursor populations between genotypes. As illustrated in Figure 5, thymidine incorporation by VavCre^+ $\text{SOCS-3}^{-/\Delta}$ Gr-1^+ cells was significantly increased at all concentrations studied. Proliferation induced by the control

- 50 -

stimulus, IL-3, was normal, excluding an inherent proliferative advantage of cells unrelated to a specific stimulus.

Furthermore, the survival of $\text{vavCre}^+\text{SOCS3}^{-/\Delta}$ Gr-1^{hi} cells (a population highly enriched for neutrophils and metamyelocytes, but not precursors with mitotic potential) was enhanced after 48 hours in culture in response to G-CSF.

To examine G-CSFR expression, bone marrow cells from $\text{vavCre}^+\text{SOCS3}^{-/\text{fl}}$ and control mice were incubated with radiolabeled G-CSF in the presence and absence of excess unlabeled G-CSF. No differences in the numbers of G-CSFR were observed between genotypes ($\text{vavCre}^+\text{SOCS3}^{-/\text{fl}}$, 1699 ± 72 cpm; $\text{vavCre}^-\text{SOCS3}^{+/\text{fl}}$, 1884 ± 248 cpm), eliminating this as an explanation for the differences in cellular responses. In contrast, the duration and intensity of STAT3 phosphorylation was increased in lysates of bone marrow cells after a 15 min pulse with G-CSF in vitro. These in vitro data prove that expression of SOCS3 regulates both STAT3 phosphorylation and the proliferation and survival of myeloid cells in response to G-CSF.

EXAMPLE 9

SOCS-3 is required to negatively regulate emergency granulopoiesis

20

The above *in vitro* data predict that SOCS-3 is required to negatively regulate granulopoiesis under stress conditions characterized by high levels of circulating G-CSF, i.e. emergency granulopoiesis. To mimic this situation, VavCre^+ SOCS-3^{-/^{fl}} mice and VavCre^- SOCS-3^{+/^{fl}} controls were injected for four days with either pharmacological doses of G-CSF, or vehicle. Originally, five days of injection were planned, however G-CSF-injected VavCre^+ SOCS-3^{-/^{fl}} mice demonstrated severe lethargy and intermittent hind-leg paresis after four days and the experiment was modified accordingly. Wild-type mice never display such toxicity from G-CSF, even at substantially higher doses.

- 51 -

No differences were observed between genotypes when injected with vehicle only. However, *in vivo* responses to G-CSF were markedly accentuated in VavCre⁺ SOCS-3^{-fl} mice. These are summarized in Figure 6.

5 As well as striking neutrophilia, progenitor cell mobilisation and splenomegaly, all VavCre⁺ SOCS-3^{-fl} mice displayed increased tissue infiltration with neutrophils on histological analysis (tissues included the liver, spinal cord and muscle). This was particularly marked in two of four mice which displayed pathological microabscess formation within the liver parenchyma. In one mouse, whole areas of bone marrow were
10 replaced with degenerate neutrophils and their debris, reflecting inappropriate cell death. Further, evidence of pathological neutrophil death was also seen in this particular mouse in the aforementioned hepatic microabscesses.

No such changes were observed in control mice injected with G-CSF. In addition, the
15 hematological and histological parameters of vehicle-injected vavCre⁺SOCS3^{-fl} mice were identical to vehicle-injected control mice.

Based on our detailed survey of vavCre⁺R26R lacZ reporter mice, endothelial cells in vavCre⁺SOCS3^{-fl} mice are very likely to be SOCS3-deficient, and therefore it is possible
20 that the pathological responses observed in the above experiment were contributed to by loss of SOCS3 expression in tissues other than the hematopoietic system. A further caveat in interpreting these data is the hemizygosity of SOCS3 in all other tissues and the possibility that this may have contributed to the breadth of pathology observed. To confirm that the enhanced responses were principally intrinsic to the hematopoietic system,
25 radiation chimeras were created in which the hematopoietic compartment was SOCS3-deficient and all other tissues were wild-type. SOCS3 wild-type C57BL/6.SJL (Ptprc^a Pep3^b (Ly5.1)) recipient mice were reconstituted with C57BL/6 (Ptprc^b Pep3^a (Ly5.2)) SOCS3-deficient or control fetal liver cells and then treated with the same dose of G-CSF for 4 days and analysed on day 5. Recipients of either SOCS3-deficient or control vavCre⁻
30 SOCS3^{+fl} cells demonstrated efficient reconstitution by donor cells (>90% of cells in all hematopoietic lineages as judged by expression of Ly5.2).

- 52 -

Mice reconstituted with SOCS3-deficient hematopoietic cells were clearly hyperresponsive to G-CSF, with augmented progenitor cell mobilization and greater splenomegaly than recipients of control cells, but some differences in haematological parameters and in the degree of tissue pathology were evident between these mice and $\text{vavCre}^+\text{SOCS3}^{-/\text{fl}}$ mice. After G-CSF injection for 4 days, there was a near absence of mature neutrophils in the bone marrow of mice reconstituted with SOCS3-deficient cells. Surprisingly, these mature neutrophils were not detected in increased numbers in the blood as was observed for $\text{vavCre}^+\text{SOCS3}^{-/\text{fl}}$ mice injected with G-CSF, but rather were found in large numbers in the tissues, particularly the liver and lungs. Mice injected with G-CSF for 8 days did display a neutrophilia greater than observed for controls, ultimately recapitulating the pattern of differences observed in $\text{vavCre}^+\text{SOCS3}^{-/\text{fl}}$ mice. The degree of enhancement of G-CSF response observed in transplant recipients of SOCS3-deficient cells was not as marked as observed for $\text{vavCre}^+\text{SOCS3}^{-/\text{fl}}$ over control mice. Further, neutrophil infiltration of the spinal cord following G-CSF injection was not observed in mice reconstituted with SOCS3-deficient cells. These data indicate that while the hematopoietic cell hyperresponsiveness to G-CSF is primarily responsible for the aberrant tissue infiltration and pathology, loss of SOCS3 expression by other cells, for example endothelial cells, must also contribute to the severity of the phenotype.

EXAMPLE 10

Recruitment and activation of SOCS3-deficient neutrophils

The pathological tissue infiltration and damage by neutrophils observed in both G-CSF injected mice with SOCS3-deficient hematopoiesis, and aging $\text{vavCre}^+\text{SOCS3}^{-/\text{fl}}$ mice, suggests that abnormalities in neutrophil recruitment and activity may exist. In order to analyse the survival and function of mature neutrophils in response to an inflammatory stimulus, mice were injected intraperitoneally with casein. Recruitment of neutrophils to the peritoneal cavity 3 hours following the installation of casein was normal ($\text{vavCre}^+\text{SOCS3}^{-/\text{fl}}$, $5 \pm 4 \times 10^6$ neutrophils; $\text{vavCre}^+\text{SOCS3}^{+/+\text{fl}}$, $5 \pm 4 \times 10^6$ neutrophils, $n=5-10$ per group). The percentages of dying cells within the freshly harvested peritoneal

- 53 -

lavages were similar between genotypes. To further investigate survival of SOCS3-deficient neutrophils after exposure to inflammatory milieu, the peritoneal exudate cells were cultured at 37°C for 8 hours in media alone, or media supplemented with either G-CSF or GM-CSF. The survival of the inflammatory cells in media was unaffected by the
5 absence of SOCS3 ($\text{vavCre}^+\text{SOCS3}^{-/\text{fl}}$, $40 \pm 11\%$ PI^+ ; $\text{vavCre}^-\text{SOCS3}^{+/ \text{fl}}$, $39 \pm 10\%$ PI^+ , $n=4-7$ per group), as was survival in the presence of G-CSF or GM-CSF. Finally, as a measure of the functional activity of tissue neutrophils from sites of inflammation, superoxide production was measured. Superoxide production by SOCS3-deficient
10 neutrophils was normal in response to fMLP, with or without G-CSF priming, as well as with a maximal stimulation by PMA. No superoxide production was detected with G-CSF priming alone.

Those skilled in the art will appreciate that the invention described herein is susceptible to
15 variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or
20 more of said steps or features.

BIBLIOGRAPHY

- Alexander *et al.*, *Blood* 87(6): 2162-2170, 1996
- Alexander *et al.*, *Cell* 98(5): 597-608, 1999
- Avalos, *Blood* 88(3): 761-777, 1996
- Bandyopadhyay and Temin, *Mol. Cell. Biol.* 4: 749-754, 1984
- Berglund *et al.*, *Biotechnology* 11: 916-920, 1993
- Berkner *et al.*, *BioTechniques* 6: 616-629, 1988
- Berkner, *Curr. Top. Microbiol. Immunol.* 158: 39-66, 1992
- Breakefield and Geller, *Mol. Neurobiol.* 1: 339-371, 1987
- Buchsacher and Panganiban, *J. Virol.* 66: 2731-2739, 1982
- Cai *et al.*, *Development* 127: 3021-3030, 2000
- Croker *et al.*, *Nat Immunol.* 4(6): 54-545, 2003
- Croker *et al.*, *Immunol. Cell Biol.* 80(3): 231-240, 2002
- de Koning *et al.*, *Blood* 87(4): 1335-1342, 1996
- Erickson *et al.*, *Science* 249: 527-533, 1990
- Fink *et al.*, *Ann. Rev. Neurosci.* 19: 265-287, 1996
- Fink *et al.*, *Hum. Gene Ther.* 3: 11-19, 1992
- Freese *et al.*, *Biochem. Pharmacol.* 40: 2189-2199, 1990
- Gorziglia and Kapikian, *J. Virol.* 66: 4407-4412, 1992
- Greenhalgh and Hilton, *J. Leukoc. Biol.* 70(3): 348-356, 2001
- Greenhalgh *et al.*, *Molecular Endocrinology* 16(6): 1394-1406, 2002
- Helseth *et al.*, *J. Virol.* 64: 2416-2420, 1990
- Hodgson, *Bio/Technology* 9: 19-21, 1991
- Hortner *et al.*, *J. Immunol.* 169(3): 1219-1927, 2002
- Johnson *et al.*, *J. Virol.* 66: 2952-2965, 1992
- Krebs and Hilton, *J. Cell Sci.* 113(16): 2813-2819, 2000
- Kyte and Doolittle, *J. Mol. Biol.* 157: 105-132, 1982

- 55 -

- Lee *et al.*, *Science* 268: 836-844, 1995
- Lindeman *et al.*, *Genes Dev.* 15(13): 1631-1636, 2001
- Liu *et al.*, *Genes Dev.* 11(2): 179-186, 1997
- Ma *et al.*, *Cell* 87: 43-52, 1996
- Madzak *et al.*, *J. Gen. Virol.* 73: 1533-1536, 1992
- Mann and Baltimore, *J. Virol.* 54: 401-407, 1985
- Margolskee, *Curr. Top., Microbiol. Immunol.* 158: 67-95, 1992
- Marine *et al.*, *Cell* 98(5): 609-616, 1999
- Marine *et al.*, *Cell* 98(5): 617-627, 1999
- Mathews *et al.*, *Endocrinology* 123(6): 2827-2833, 1988
- Matsumoto *et al.*, *Mol. Cell Biol.* 19(9): 6396-6407, 1999
- Metcalf *et al.*, *Nature* 405(6790): 1069-1073, 2000
- Miller *et al.*, *J. Virol.* 62: 4337-4345, 1988
- Miller *et al.*, *Mol. Cell. Biol.* 5: 431-437, 1985
- Miller, *Curr. Top. Microbiol. Immunol.* 158: 1-24, 1992
- Moss, *Curr. Top. Microbiol. Immunol.* 158: 25-38, 1992
- Moss, *Proc. Natl. Acad. Sci. USA* 93: 11341-11348, 1996
- Munder *et al.*, *Appl. Microbiol. Biotechnol.* 52(3): 311-320, 1999
- Muzyczka, *Curr. Top. Microbiol. Immunol.* 158: 97-129, 1992
- Naldini *et al.*, *Science* 272: 263-267, 1996
- Nicholson *et al.*, *Proc. Natl. Acad. Sci. USA* 91(8): 2985-2988, 1994
- Nieto *et al.*, *Neuron* 29: 401-413, 2001
- Ogilvy *et al.*, *Blood* 94(6): 1855-1863, 1999
- Ohi *et al.*, *Gene* 89: 279-282, 1990
- Page *et al.*, *J. Virol.* 64: 5270-5276, 1990
- Palmiter *et al.*, *Science* 222(4625): 809-814, 1983
- Petropoulos *et al.*, *J. Virol.* 66: 3391-3397, 1992
- Polizzotto *et al.*, *J Comp Neurol* 423: 348-358, 2000

- 56 -

- Quantin *et al.*, *Proc. Natl. Acad. Sci. USA* 89: 2581-2584, 1992
- Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing, Company, Easton, PA, U.S.A
- Roberts *et al.*, *Exp. Hematol.* 22(12): 1156-1163, 1994
- Roberts *et al.*, *Proc. Natl. Acad. Sci. USA* 98(16): 9324-9329, 2001
- Rosenfeld *et al.*, *Cell* 68: 143-155, 1992
- Russell and Hirata, *Nature Genetics* 18: 323-328, 1998
- Schneider *et al.*, *Nature Genetics* 18: 180-183, 1998
- Shimada *et al.*, *J. Clin. Invest.* 88: 1043-1047, 1991
- Sorge *et al.*, *Mol. Cell. Biol.* 4: 1730-1737, 1984
- Soriano *et al.*, *Nat. Genet.* 21(1): 70-71, 1999
- Starr *et al.*, *Nature* 387(6636): 917-921, 1997
- Stratford-Perricaudet *et al.*, *Hum. Gene Ther.* 1: 241-256, 1990
- Summerton and Weller, *Antisense and Nucleic Acid Drug Development* 7: 187-195, 1997
- Sun *et al.*, *Cell* 104: 365-376, 2001
- Teglund *et al.*, *Cell* 93(5): 841-850, 1998
- Tian *et al.*, *Blood* 84(6): 1760-1764, 1994
- Tian *et al.*, *Blood* 88(12): 4435-4444, 1996
- Udy *et al.*, *Proc. Natl. Acad. Sci. USA* 94(14): 7239-7244, 1997
- Ward *et al.*, *Blood* 93(1): 113-124, 1999
- Wells, *Methods Enzymol.* 202: 2699-2705, 1991
- Wilkinson *et al.*, *Nucleic Acids Res.* 20: 2233-2239, 1992
- Yasukawa *et al.*, *Annu. Rev. Immunol.* 18: 143-164, 2000
- Young *et al.*, *Nat. Biotechnol.* 16(10): 946-950, 1998

CLAIMS

1. An isolated compound which modulates G-CSF-induced cellular responses wherein the compound inhibits or activates G-CSF activity or levels *via* a SOCS molecule.
2. The compound of Claim 1 wherein the compound up-regulates the activity or levels of SOCS-3.
3. The compound of Claim 1 wherein the compound down-regulates the activity or levels of SOCS-3.
4. The compound of any one of Claims 1 to 3 wherein the compound is a nucleic acid molecule.
5. The compound of Claim 4 wherein the nucleic acid molecule is an oligonucleotide.
6. The compound of Claim 4 or 5 wherein the nucleic acid molecule is mRNA, RNAi, siRNA or DNA or a complex containing same.
7. The compound of Claim 6 wherein the nucleic acid molecule is a sense or antisense oligonucleotide.
8. The compound of any one of Claims 1 to 3 wherein the compound is a proteinaceous molecule.
9. The compound of any one of Claims 1 to 3 wherein the compound is a non-protein chemical.

- 58 -

10. A pharmaceutical composition comprising a component of any one of Claims 1 to 11 and one or more pharmaceutically acceptable carriers and/or diluents.
11. The pharmaceutical composition of Claim 10 wherein the composition is a nucleic acid molecule.
12. The pharmaceutical composition of Claim 11 wherein the composition is a gene therapy composition.
13. A method for modulating G-CSF-induced cellular responses in a mammal, said method comprising administering to said mammal an effective amount of a compound of any one of Claims 1 to 9 or a composition of Claim 10 or 11 or 12.
14. The method of Claim 13 wherein the mammal is a human.
15. The method of Claim 13 or 14 wherein the compound inhibits or elevates levels of SOCS-3.
16. An animal model useful for screening for compounds which modulate G-CSF-induced cellular responses, said model comprising a genetically modified animal which comprises cells which produce elevated or reduced levels of SOCS-3.
17. The animal model of Claim 16 wherein the animal is a non-human primate, lower primate, mouse, rat, rabbit, sheep, goat or pig.

1/6




Figure 1




Figure 2

3/6




Figure 3




Figure 4





Figure 5

**Figure 6**

- 1 -

SEQUENCE LISTING

<110> The Walter and Eliza Hall Institute of Medical Research

<120> Active compounds and uses therefor

<130> 12456910/EJH

<140> AU 2003902788

<141> 2003-06-04

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 682

<212> DNA

<213> human

<220>

<221> CDS

<222> (1)..(678)

<223>

<400> 1

atg gtc acc cac agc aag ttt ccc gcc gcc ggg atg agc cgc ccc ctg	48
Met Val Thr His Ser Lys Phe Pro Ala Ala Gly Met Ser Arg Pro Leu	
1 5 10 15	

gac acc agc ctg cgc ctc aag acc ttc agc tcc aag agc gag tac cag	96
Asp Thr Ser Leu Arg Leu Lys Thr Phe Ser Ser Lys Ser Glu Tyr Gln	
20 25 30	

ctg gtg gtg aac gca gtg cgc aag ctg cag gag agc ggc ttc tac tgg	144
Leu Val Val Asn Ala Val Arg Lys Leu Gln Glu Ser Gly Phe Tyr Trp	
35 40 45	

agc gca gtg acc ggc ggc gag gcg aac ctg ctg ctc agc gcc gag ccc	192
Ser Ala Val Thr Gly Gly Glu Ala Asn Leu Leu Ser Ala Glu Pro	
50 55 60	

gcc ggc acc ttt ctg atc cgc gac agc tcg gac cag cgc cac ttc ttc	240
Ala Gly Thr Phe Leu Ile Arg Asp Ser Ser Asp Gln Arg His Phe Phe	
65 70 75 80	

acg ctc agc gtc aag acc cag tct ggg acc aag aac ctg cgc atc cag	288
Thr Leu Ser Val Lys Thr Gln Ser Gly Thr Lys Asn Leu Arg Ile Gln	
85 90 95	

tgt gag ggg ggc agc ttc tct ctg cag agc gat ccc cgg agc acg cag	336
Cys Glu Gly Gly Ser Phe Ser Leu Gln Ser Asp Pro Arg Ser Thr Gln	
100 105 110	

ccc gtg ccc cgc ttc gac tgc gtg ctc aag ctg gtg cac cac tac atg	384
Pro Val Pro Arg Phe Asp Cys Val Leu Lys Leu Val His His Tyr Met	
115 120 125	

- 2 -

ccg ccc cct gga gcc ccc tcc ttc ccc tcg cca cct act gaa ccc tcc 432
 Pro Pro Pro Gly Ala Pro Ser Phe Pro Ser Pro Pro Thr Glu Pro Ser
 130 135 140

tcc gag gtg ccc gag cag ccg tct gcc cag cca ctc cct ggg agt ccc 480
 Ser Glu Val Pro Glu Gln Pro Ser Ala Gln Pro Leu Pro Gly Ser Pro
 145 150 155 160

ccc aga aga gcc tat tac atc tac tcc ggg ggc gag aag atc ccc ctg 528
 Pro Arg Arg Ala Tyr Tyr Ile Tyr Ser Gly Gly Glu Lys Ile Pro Leu
 165 170 175

gtg ttg agc cgg ccc ctc tcc tcc aac gtg gcc act ctt cag cat ctc 576
 Val Leu Ser Arg Pro Leu Ser Ser Asn Val Ala Thr Leu Gln His Leu
 180 185 190

tgt cgg aag acc gtc aac ggc cac ctg gac tcc tat gag aaa gtc acc 624
 Cys Arg Lys Thr Val Asn Gly His Leu Asp Ser Tyr Glu Lys Val Thr
 195 200 205

cag ctg ccg ggg ccc att cgg gag ttc ctg gac cag tac gat gcc ccg 672
 Gln Leu Pro Gly Pro Ile Arg Glu Phe Leu Asp Gln Tyr Asp Ala Pro
 210 215 220

ctt taa gggg 682
 Leu
 225

<210> 2
 <211> 225
 <212> PRT
 <213> human

<400> 2

Met Val Thr His Ser Lys Phe Pro Ala Ala Gly Met Ser Arg Pro Leu
 1 5 10 15

Asp Thr Ser Leu Arg Leu Lys Thr Phe Ser Ser Lys Ser Glu Tyr Gln
 20 25 30

Leu Val Val Asn Ala Val Arg Lys Leu Gln Glu Ser Gly Phe Tyr Trp
 35 40 45

Ser Ala Val Thr Gly Gly Glu Ala Asn Leu Leu Leu Ser Ala Glu Pro
 50 55 60

Ala Gly Thr Phe Leu Ile Arg Asp Ser Ser Asp Gln Arg His Phe Phe
 65 70 75 80

Thr Leu Ser Val Lys Thr Gln Ser Gly Thr Lys Asn Leu Arg Ile Gln
 85 90 95

Cys Glu Gly Gly Ser Phe Ser Leu Gln Ser Asp Pro Arg Ser Thr Gln
 100 105 110

Pro Val Pro Arg Phe Asp Cys Val Leu Lys Leu Val His His Tyr Met

- 3 -

115	120	125	
Pro Pro Pro Gly Ala Pro Ser Phe Pro Ser Pro Pro Thr Glu Pro Ser			
130	135	140	
Ser Glu Val Pro Glu Gln Pro Ser Ala Gln Pro Leu Pro Gly Ser Pro			
145	150	155	160
Pro Arg Arg Ala Tyr Tyr Ile Tyr Ser Gly Gly Glu Lys Ile Pro Leu			
	165	170	175
Val Leu Ser Arg Pro Leu Ser Ser Asn Val Ala Thr Leu Gln His Leu			
	180	185	190
Cys Arg Lys Thr Val Asn Gly His Leu Asp Ser Tyr Glu Lys Val Thr			
	195	200	205
Gln Leu Pro Gly Pro Ile Arg Glu Phe Leu Asp Gln Tyr Asp Ala Pro			
210	215	220	
Leu			
225			
<210> 3			
<211> 2187			
<212> DNA			
<213> murine			
<220>			
<221> CDS			
<222> (18) .. (692)			
<223>			
<400> 3			
cgctggctcc gtgcgcc atg gtc acc cac agc aag ttt ccc gcc gcc ggg			50
Met Val Thr His Ser Lys Phe Pro Ala Ala Gly			
1 5 10			
atg agc cgc ccc ctg gac acc agc ctg cgc ctc aag acc ttc agc tcc			98
Met Ser Arg Pro Leu Asp Thr Ser Leu Arg Leu Lys Thr Phe Ser Ser			
15 20 25			
aaa agc gag tac cag ctg gtg gtg aac gcc gtg cgc aag ctg cag gag			146
Lys Ser Glu Tyr Gln Leu Val Val Asn Ala Val Arg Lys Leu Gln Glu			
30 35 40			
agc gga ttc tac tgg agc gcc gtg acc ggc ggc gag gcg aac ctg ctg			194
Ser Gly Phe Tyr Trp Ser Ala Val Thr Gly Gly Glu Ala Asn Leu Leu			
45 50 55			
ctc agc gcc gag ccc gcg ggc acc ttt ctt atc cgc gac agc tcg gac			242
Leu Ser Ala Glu Pro Ala Gly Thr Phe Leu Ile Arg Asp Ser Ser Asp			
60 65 70 75			
cag cgc cac ttc ttc acg ttg agc gtc aag acc cag tcg ggg acc aag			290
Gln Arg His Phe Phe Thr Leu Ser Val Lys Thr Gln Ser Gly Thr Lys			
80 85 90			

- 4 -

aac cta cgc atc cag tgt gag ggg ggc agc ttt tcg ctg cag agt gac	338
Asn Leu Arg Ile Gln Cys Glu Gly Gly Ser Phe Ser Leu Gln Ser Asp	
95 100 105	
ccc cga agc acg cag cca gtt ccc cgc ttc gac tgt gta ctc aag ctg	386
Pro Arg Ser Thr Gln Pro Val Pro Arg Phe Asp Cys Val Leu Lys Leu	
110 115 120	
gtg cac cac tac atg ccg cct cca ggg acc ccc tcc ttt tct ttg cca	434
Val His His Tyr Met Pro Pro Pro Gly Thr Pro Ser Phe Ser Leu Pro	
125 130 135	
ccc acg gaa ccc tcg tcc gaa gtt ccg gag cag cca cct gcc cag gca	482
Pro Thr Glu Pro Ser Ser Glu Val Pro Glu Gln Pro Pro Ala Gln Ala	
140 145 150 155	
ctc ccc ggg agt acc ccc aag aga gct tac tac atc tat tct ggg ggc	530
Leu Pro Gly Ser Thr Pro Lys Arg Ala Tyr Tyr Ile Tyr Ser Gly Gly	
160 165 170	
gag aag att ccg ctg gta ctg agc cga cct ctc tcc tcc aac gtg gcc	578
Glu Lys Ile Pro Leu Val Leu Ser Arg Pro Leu Ser Ser Asn Val Ala	
175 180 185	
acc ctc cag cat ctt tgt cgg aag act gtc aac ggc cac ctg gac tcc	626
Thr Leu Gln His Leu Cys Arg Lys Thr Val Asn Gly His Leu Asp Ser	
190 195 200	
tat gag aaa gtg acc cag ctg cct gga ccc att cgg gag ttc ctg gat	674
Tyr Glu Lys Val Thr Gln Leu Pro Gly Pro Ile Arg Glu Phe Leu Asp	
205 210 215	
cag tat gat gct cca ctt taaggagcaa aagggtcaga ggggggcctg	722
Gln Tyr Asp Ala Pro Leu	
220 225	
ggtcgggtcgg tcgcctctcc tccgaggcac atggcacaag cacaaaaatc cagccccaac	782
ggtcgggtagc tcccagtgag ccaggggcag attggcttct tcctcaggcc ctccactccc	842
gcagagtaga gctggcagga cctggaattc gtctgagggg agggggagct gccacctgct	902
ttccccctc cccagctcc agcttcttcc aagtggagcc agccggcctg gcctgggtggg	962
acaatacctt tgacaagcgg actctcccct ccccttcctc cacaccccct ctgcttccca	1022
aggagaggtgg ggacacctcc aagtgttgaa cttagaactg caaggggaat cttcaaactt	1082
tcccgctgga acttgtttgc gctttgatth ggtttgatca agagcaggca cctgggggaa	1142
ggatggaaga gaaaaggggtg tgtgaagggt ttttatgctg gccaaagaaa taaccactcc	1202
cactgcccac cctaggtgag gagggtggc tcctggctct ggggagagt gcaaggggtg	1262
acctgaagag agctatactg gtgccaggct cctctccatg gggcagctaa tgaaacctcg	1322
cagatccctt gcaccccaga accctccccg ttgtgaagag gcagtagcat ttagaagggg	1382

- 5 -

gacagatgag gctgggtgagc tggccgcctt ttccaacacc gaaggaggagc agatcaacag 1442
 atgagccatc ttggagccca ggtttccctt ggagcagatg gaggggttctg ctttgtctct 1502
 cctatgtggg gctaggagac tcgccttaaa tgcctctgtg cccagggatg gggattggca 1562
 cacaaggagc caaacacagc caataggcag agagttgagg gattcaccca ggtggctaca 1622
 ggccagggga agtggctgca ggggagagac ccagtcactc caggagactc ctgagttaac 1682
 actgggaaga cattggccag tcctagtcac ctctcgggtca gtaggtccga gagcttccag 1742
 gccctgcaca gccctccttt ctacactggg gggaggcagg aggtgatgga gaagccttcc 1802
 catgccgctc acaggggcct cacgggaatg cagcagccat gcaattacct ggaactggtc 1862
 ctgtgttggg gagaaacaag ttttctgaag tcaggtatgg ggctgggtgg ggcagctgtg 1922
 tgttgggggtg gcttttttct ctctgttttg aataatgttt acaatttgcc tcaatcactt 1982
 ttataaaaat ccacctccag cccgcccctc tccccactca ggccttcgag gctgtctgaa 2042
 gatgcttgaa aaactcaacc aaatcccagt tcaactcaga ctttgcacat atatttatat 2102
 ttataactcag aaaagaaaca tttcagtaat ttataataaa agagcactat tttttaatga 2162
 aaaaaaaaaa aaaaaaaaaa aaaaa 2187

<210> 4
 <211> 225
 <212> PRT
 <213> murine

<400> 4

Met	Val	Thr	His	Ser	Lys	Phe	Pro	Ala	Ala	Gly	Met	Ser	Arg	Pro	Leu
1				5					10					15	
Asp	Thr	Ser	Leu	Arg	Leu	Lys	Thr	Phe	Ser	Ser	Lys	Ser	Glu	Tyr	Gln
			20					25					30		
Leu	Val	Val	Asn	Ala	Val	Arg	Lys	Leu	Gln	Glu	Ser	Gly	Phe	Tyr	Trp
			35				40					45			
Ser	Ala	Val	Thr	Gly	Gly	Glu	Ala	Asn	Leu	Leu	Leu	Ser	Ala	Glu	Pro
			50			55					60				
Ala	Gly	Thr	Phe	Leu	Ile	Arg	Asp	Ser	Ser	Asp	Gln	Arg	His	Phe	Phe
65					70					75				80	
Thr	Leu	Ser	Val	Lys	Thr	Gln	Ser	Gly	Thr	Lys	Asn	Leu	Arg	Ile	Gln
				85					90					95	
Cys	Glu	Gly	Gly	Ser	Phe	Ser	Leu	Gln	Ser	Asp	Pro	Arg	Ser	Thr	Gln
			100					105					110		
Pro	Val	Pro	Arg	Phe	Asp	Cys	Val	Leu	Lys	Leu	Val	His	His	Tyr	Met
			115				120					125			

- 6 -

Pro Pro Pro Gly Thr Pro Ser Phe Ser Leu Pro Pro Thr Glu Pro Ser
130 135 140

Ser Glu Val Pro Glu Gln Pro Pro Ala Gln Ala Leu Pro Gly Ser Thr
145 150 155 160

Pro Lys Arg Ala Tyr Tyr Ile Tyr Ser Gly Gly Glu Lys Ile Pro Leu
165 170 175

Val Leu Ser Arg Pro Leu Ser Ser Asn Val Ala Thr Leu Gln His Leu
180 185 190

Cys Arg Lys Thr Val Asn Gly His Leu Asp Ser Tyr Glu Lys Val Thr
195 200 205

Gln Leu Pro Gly Pro Ile Arg Glu Phe Leu Asp Gln Tyr Asp Ala Pro
210 215 220

Leu
225

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2004/000749

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁷ : C12Q 1/68 C12N 15/00 A01K 67/00 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) See electronic database Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched See electronic database Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS; MEDLINE; CAPLUS: SOCS, suppressor cytokine signaling, G-CSF, granulocyte colony stimulating factor														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X	Matsumoto et al (2003) 'A role of suppressor of cytokine signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated Interleukin 2 Production' The Journal of Experimental Medicine. Vol 197(4): 425-436 See in particular 4 th paragraph, page 427	16, 17												
X, Y	Croker et al (2003) 'SOCS3 negatively regulates IL-6 signaling <i>in vivo</i> ' Nature Immunology. Vol 4(6): 540-545 Published online May 18 2003 See in particular page 541	16, 17												
☒ Further documents are listed in the continuation of Box C ☐ See patent family annex														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td></td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:		"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:														
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family													
"P" document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 20 August 2004		Date of mailing of the international search report 26 AUG 2004												
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer LEXIE PRESS Telephone No : (02) 6283 2677												

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2004/000749

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Georgiades et al (2002) 'vavCre Transgenic mice: A tool for mutagenesis in hematopoietic and endothelial lineages' Genesis. Vol 34: 251-256 See the whole document	16, 17
X	Hörtner et al (2002) 'Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction' The Journal of Immunology. Vol 169: 1219-1227 See the whole document	13 to 15
X	Hermans et al (2003) 'Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid cells' Blood. Vol 101(7): 2584-2590 See the whole document	13 to 15
P, X	Croker et al (2004) 'SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis' Immunity. Vol 20: 153-165 See the whole document	1 to 17
P, X	Kimura et al (2004) 'SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling' The Journal of Biological Chemistry. Vol 279(8): 6905-6910 See the whole document	1 to 17
P, X	Van de Geijn et al (2004) 'Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling' Journal of Leukocyte Biology. Vol 76: 237-244 See the whole document	1 to 15
P, X	Van de Geijn et al (2004) 'G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact' Blood. Vol 104(3): 667-674 See the whole document	1 to 15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2004/000749

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: **1 to 12**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

See supplemental sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2004/000749

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: V

Claims 1 to 12 relate to a disproportionately large number of possible compounds which are not supported by the description according to Article 6 PCT or can be considered disclosed according to Article 5 PCT. Claims 1 to 12 lack the appropriate support and the patent application lacks the required disclosure to such an extent that a meaningful search encompassing the entire scope of claims 1-12 is impossible. For this reason the search was directed at the inventive concept of the invention which appears to be the use of a transgenic animal with altered levels of SOCS3 to determine compounds that modulate G-CSF activity by modulating SOCS3 activity.

The Applicant's attention is drawn to the fact that claims, or parts of claims relating to inventions in respect of which no International Search Report has been established need not be the subject of an International Preliminary Examination.